BioCryst Pharmaceuticals
BCRX
BCRX
120 hedge funds and large institutions have $439M invested in BioCryst Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 42 increasing their positions, 28 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
1.07% less ownership
Funds ownership: 85.89% → 84.81% (-1.1%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
77% less call options, than puts
Call options by funds: $1.1M | Put options by funds: $4.83M
Holders
120
Holding in Top 10
2
Calls
$1.1M
Puts
$4.83M
Top Buyers
| 1 | +$23.8M | |
| 2 | +$11.9M | |
| 3 | +$9.55M | |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$8.58M |
| 5 |
DM
Deerfield Management
New York
|
+$7.74M |
Top Sellers
| 1 | -$4.93M | |
| 2 | -$3.12M | |
| 3 | -$2.95M | |
| 4 |
UONDDL
University of Notre Dame du Lac
South Bend,
Indiana
|
-$2.35M |
| 5 |
PC
Paulson & Co
New York
|
-$1.94M |